Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Colorcon
Cantor Fitzgerald
Julphar
Chinese Patent Office
Boehringer Ingelheim
US Department of Justice
Fuji
Merck

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIENTINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Trientine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00004339 Study of Tetrathiomolybdate in Patients With Wilson Disease Completed University of Michigan Phase 3 OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
NCT00004339 Study of Tetrathiomolybdate in Patients With Wilson Disease Completed National Center for Research Resources (NCRR) Phase 3 OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
NCT00212355 Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. Completed Nobelpharma Phase 3 The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
NCT01178112 Trientine and Carboplatin in Advanced Malignancies Completed M.D. Anderson Cancer Center Phase 1 The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
NCT01213888 Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy Terminated University of British Columbia N/A To evaluate the effects of Trientine Hydrochloride in prevention of post-laser (pan-retinal photocoagulation) macular edema in the eyes for subjects with diabetic retinopathy. Trientine hydrochloride can limit secondary inflammatory damage to retinal vessels following the administration of pan-retinal photocoagulation therapy for severe non-proliferative diabetic retinopathy or retinal neovascularization due to diabetic retinopathy, resulting in less macular edema and improved visual outcomes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Trientine Hydrochloride

Condition Name

Condition Name for Trientine Hydrochloride
Intervention Trials
Wilson Disease 5
Wilson's Disease 2
Melanoma 1
Macular Edema Following Cataract Surgery 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trientine Hydrochloride
Intervention Trials
Hepatolenticular Degeneration 7
Macular Edema 2
Diabetes Mellitus 1
Cataract 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trientine Hydrochloride

Trials by Country

Trials by Country for Trientine Hydrochloride
Location Trials
United States 11
Germany 4
United Kingdom 3
Canada 2
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trientine Hydrochloride
Location Trials
Connecticut 3
Michigan 2
Washington 1
Tennessee 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trientine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Trientine Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trientine Hydrochloride
Clinical Trial Phase Trials
Completed 5
Recruiting 2
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trientine Hydrochloride

Sponsor Name

Sponsor Name for Trientine Hydrochloride
Sponsor Trials
University of British Columbia 2
Univar BV 2
Yale University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trientine Hydrochloride
Sponsor Trials
Industry 7
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Deloitte
Baxter
Julphar
Teva
Moodys
Fuji
US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.